MannKind's pipeline and collaborations to develop and advance new products and help people take control of their health. Explore our pipeline and collaborations.
At MannKind, we want to help people experience the best that life has to offer. Learn how MannKind is dedicated to helping more people live life more humann.
What’s new at MannKind? From announcements to financial results, learn the latest about MannKind Corporation by reading our press releases and about our events.
The MannKind team is an inspired community, fueled by the diverse experience and ideas of our people and partners. Learn more about our career opportunities.
At MannKind, our commitment to clinical trials underscores our unwavering dedication to the well-being and safety of patients, along with our unrelenting pursuit of medical innovation. By dedicating substantial time, resources, and expertise to the meticulous execution of rigorous clinical trials, we firmly uphold the highest standards of scientific integrity.
The Investor Relations website contains information about MannKind Corporation's business for stockholders, potential investors, and financial analysts.
MannKind’s Technosphere powders are delivered into the lung’s airstream via an inhalation device or DPI (dry powder inhaler). The breath-powered inhalers (Dreamboat® being the most common version) provide excellent delivery efficiency and are proven to deliver up to 70% of the dry-powder dose deep into the lungs.
We came across a bullish thesis on MannKind Corporation on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation’s share was trading at $3.5000 as of ...
StockNews.com upgraded shares of MannKind (NASDAQ:MNKD – Free Report) from a hold rating to a buy rating in a research note released on Wednesday. A number of other research analysts also recently ...